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ORIGINAL ARTICLE
Intravenous lidocaine as adjuvant to general anesthesia in renal surgery
Mohamed Said Nakhli a, Mohamed Kahloula, Taieb Guizania, Chekib Zedinib, Ajmi Chaoucha
and Walid Naijaa
aDepartment of Anesthesia and Intensive Care, Sahloul Teaching Hospital; Faculty of Medicine ‘Ibn El Jazzar’, Sousse, Tunisia;
bDepartment of Family and Community Medicine, Faculty of Medicine ‘Ibn El Jazzar’, Sousse, Tunisia
ABSTRACT
The role of intraoperative intravenous lidocaine infusion has been previously evaluated for
pain relief, inflammatory response, and post-operative recovery, particularly in abdominal
surgery. The present study is a randomized double-blinded trial in which we evaluated
whether IV lidocaine infusion reduces isoflurane requirement, intraoperative remifentanil
consumption and time to post-operative recovery in non-laparoscopic renal surgery. Sixty
patients scheduled to undergo elective non-laparoscopic renal surgery under general
anesthesia were enrolled to receive either systemic lidocaine infusion (group L: bolus
1.5 mg/kg followed by a continuous infusion at the rate of 2 mg/kg/hr until skin closure) or
normal saline (0.9% NaCl solution) (Group C). The depth of anesthesia was monitored using
the Bispectral Index Scale (BIS), which is based on measurement of the patient’s cerebral
electrical activity. Primary outcome of the study was End-tidal of isoflurane concentration (Et-
Iso) at BIS values of 40–60. Secondary outcomes include remifentanil consumption during the
operation and time to extubation. Et-Iso was significantly lower in group L than in group C
(0.63% ± 0.10% vs 0.92% ± 0.11%, p < 10–3). Mean remifentanil consumption of was
significantly lower in group L than in group C (0.13 ± 0.04 µg/kg/min vs 0.18 ± 0.04 µg/kg/
min, p < 10–3). Thus, IV lidocaine infusion permits a reduction of 31% in isoflurane concentra-
tion requirement and 27% in the intraoperative remifentanil need. In addition, recovery from
anesthesia and extubation time was shorter in group L (5.8 ± 1.8 min vs 7.9 ± 2.0 min, p < 10–
3). By reducing significantly isoflurane and remifentanil requirements during renal surgery,
intravenous lidocaine could provide effective strategy to limit volatile agent and intraopera-
tive opioids consumption especially in low and middle income countries.
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1. Introduction
Post-operative nausea or vomiting and pain are the
main causes of discomfort and dissatisfaction of
patients following general anesthesia. They are
increased by volatile agents and high doses of opioids
[1]. By reducing the requirement for anesthetic agents,
we suppose to decrease these side effects, shorten
recovery and extubation time, and reduce anesthetic
procedure costs. Several approaches were then pro-
posed, such as intraoperative systemic lidocaine infu-
sion. Perioperative effects of intravenous lidocaine
infusion were evaluated in several animal studies
showing a reduction of minimum alveolar concentra-
tion (MAC) of volatile anesthetics and intraoperative
opioids consumption [2,3]. The mechanism of action of
lidocaine involves its binding to sodium channels and
its interaction with the general anesthetic agents
resulting in a synergic effect [4]. Lidocaine has also
been shown to possess an anti-inflammatory action,
and to prevent central hyperalgesia [5]. In humans, the
role of intraoperative systemic lidocaine [AQ] infusion
was evaluated in pain relief, cytokine response, bowel
function recovery, post-operative nausea and vomit-
ing, and length of hospital stay, particularly in abdom-
inal surgery [6–9]. However, the benefit of systemic
lidocaine infusion is still controversial when used in
others fields such as orthopedic and cardiovascular
surgeries reflecting a possible organ dependent effects
[10]. To the best of our knowledge, there is no clinical
study assessing the effect of intravenous lidocaine
infusion during general anesthesia on the total dose
of anesthetic agents required for lumbotomy. The aim
of this study is to evaluate the effect of intravenous
lidocaine on isoflurane and remifentanil requirements
during general anesthesia for renal surgery by lumbot-
omy as monitored by Bispectral Index Scale (BIS).
2. Methods
The study protocol was approved by the institutional
ethic committee of Sahloul teaching hospital. Written
informed consent was obtained. Sixty patients aged
18–80 years (Table 1) with American society of anaes-
thesiologists (ASA) physical status 1 and 2 were
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scheduled for elective lumbotomy under general
anesthesia and enrolled prospectively in this rando-
mized double-blinded study, which was conducted
between November 2015 and December 2016.
Exclusion criteria were: ASA physical status ≥ 3, history
of hepatic, renal or cardiac failure, prior lumbotomy,
morbid obesity (BMI > 40), pregnancy, chronic use of
opioids or benzodiazepines or anti-inflammatory
drugs, allergy to local anesthetics and nephrectomy
for renal transplantation. Patients with a history of
psychiatric disorder, arrhythmia or seizures were also
excluded. All the procedures were performed by the
same team of anesthesiologists and surgeons. The
study was conducted in the urology operating room
in Sahloul teaching hospital (Sousse, Tunisia). Patients
were randomized into two groups using computer-
generated randomization tables to receive either
intraoperative systemic lidocaine infusion (group L)
or normal saline (0.9% NaCl) infusion (group C).
Approximately 30 minutes before skin incision,
patients in group L (n = 30) received an IV bolus
(1.5 mg/kg) of 1% lidocaine HCl without exceeding
100 mg, this was then followed by a continuous IV
infusion of lidocaine at the rate of 2 mg/kg/hr until
skin closure. The control group (n = 30) received the
same volume of bolus and continuous infusion of
normal saline. Standard monitor was used including
ECG, end-tidal carbon dioxide level (EtCO2), non inva-
sive arterial pressure and pulse oximetry. The BIS (BIS
Vista®, USA) was also used to assess the depth of
narcosis. The end-tidal of isoflurane (Et-Iso) concentra-
tion was monitored continuously every 10 minutes
until the end of the surgical procedure using a
Draeger Primus monitor (Draeger Primus, Draeger
Medical Austria GmbH, Vienna, Austria). The anesthe-
siologist who executed the study protocol was not
blinded to the group allocation, however the anesthe-
siologist in charge of the patient in the operating
room was. All patients received the same anesthetic
protocol without premedication. Anesthesia was
induced with intravenous remifentanil 1 µg/kg during
one minute, propofol 3 mg/kg and cisatracurium
0.15 mg/kg. After tracheal intubation, anesthesia was
maintained with isoflurane in a mixture of oxygen
(50%) and air (50%). Remifentanil infusion was
adjusted between 0.1 and 0.5 µg/kg/min to maintain
systolic blood pressure within 20% of the base line. To
ensure similar anesthetic depth in all patients during
the surgical procedure, the Et-Iso concentration was
adjusted to maintain BIS in a range of 40–60. No
supplemental neuromuscular blocking agent was
given during maintenance of anesthesia. The lungs
were ventilated with a tidal volume of 6–8 ml/kg,
and the respiratory rate was adjusted to achieve nor-
mocapnia (EtCO2 30–35 mmHg). Intravenous infusion
of crystalloids was given to patients at a rate of 5 ml/
kg/hr during surgery. Hemodynamic parameters, Et-
Iso concentration and its MAC Iso were monitored
and recorded by the anesthesiologist in charge
every 10 minutes until the end of the procedure.
Surgery was performed by one of the surgeons of
the urology team, with patient in lumbotomy position
and with a retroperitoneal approach. Post-operative
analgesia was started with paracetamol 1g and nefo-
pam 20 mg given 20 minutes before the end of
surgery. Isoflurane was stopped at the end of skin
closure as well as the remifentanil. The endotracheal
tube was removed when the patient met all criteria
for extubation. The total dose of remifentanil, the
duration of anesthesia and the extubation delay
were recorded. Primary endpoint of our study was
the Et-Iso concentrations at BIS 40–60. According to
a previous study [11], a sample of 30 patients per
group was sufficient to permit a reduction of 20% in
Et-Iso concentration in the lidocaine group, with an
alpha error of 0.01 and beta error of 0.1. Secondary
endpoints included total dose of remifentanil (µg/kg/
min) infused and the time to extubation (min).
Statistical analysis was conducted using SPSS soft-
ware for windows (Version 20.0 SPSS, Inc, Chicago, Il).
The Kolmogorov-Smirnov test was used to assess vari-
ables normality distribution. Categorical variables
were analyzed by chi square test. Continuous vari-
ables were compared by student’s t test. p value less
than 0.05 was regarded as statically significant.
3. Results
Sixty patients were randomized into two groups:
Lidocaine (L) group (n = 30) and control (C) group
(n = 30). All patients completed the study successfully
without waivers. Baseline data of the two groups were
similar. There were no significant differences in the
patient’s characteristics. The numbers of pyelotomy
and nephrectomy surgeries were similar, surgery and
anesthesia duration was comparable (Table 1). No
patient experienced a serious adverse event related
to the bolus or continuous perfusion of lidocaine,
except one occasional ventricular extrasystole without
change in vital signs. No patient reported signs of
lidocaine toxicity (metallic taste, paresthesias,




(n = 30) P
Age (years) 59 ± 12 53 ± 14 0.11
Gender male/female (n) 19/11 20/10 0.78
ASA 1/2 (n) 19/11 22/8 0.40
BMI kg.m−2 25.2 ± 4.3 26.7 ± 4.8 0.18
Type of surgery:
Pyelotomy (n)/Nephrectomy (n) 19/11 21/9 0.58
Duration of surgery (min) 78.8 ± 25.1 76.9 ± 28.0 0.78
Duration of anesthesia (min) 97.5 ± 25.6 95.3 ± 28.6 0.75
Data are reported as mean (± SD) or numbers of patients; C: Group
control; L: Group lidocaine; ASA: American Society of Anesthesiologists;
BMI: body mass index
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dizziness, blurred vision, tinnitus, perioral numbness,
drowsiness, restlessness) in the post anesthesia unit
care. Regarding the BIS which was measured every
10 minutes, its value was comparable in both groups
in the different measurement points, p > 0.05
(Figure 1). Mean blood pressure was similar through-
out anesthesia between group C and L, with p > 0.05.
However, heart rate was significantly lower in group L,
p < 0.05 (figure 2 and 3). In the lidocaine group, it was
possible to lower the end tidal and the minimum
alveolar isoflurane concentrations (Et-Iso and MAC,
respectively) that were required to maintain the BIS
value between 40 and 60 (figure 4 and 5). Average Et-
Iso concentration was 0.63% ± 0.10% and
0.92% ± 0.11% in group L and C respectively (p < 10–
3). The mean difference between Et-Iso concentration
in the lidocaine group and the control group was
0.29%, which is a relative reduction of approximately
31% in the isoflurane concentration requirement.
Moreover, the total dose of remifentanil given to
patients in the group L was lower than the one admi-
nistered to group C: 0.13 ± 0.04 µg/kg/min vs
0.18 ± 0.04 µg/kg/min (p < 10–3). Thus, IV lidocaine
allowed a 27% reduction in the total dose of remifen-
tanil used during the operation. At the end of surgery,
the time to extubation was 5.8 ± 1.8 min for group L
and 7.9 ± 2.0 min for group C (p < 10–3), a 26%
reduction in recovery time. No patient needed a rever-
sal of curare-induced neuromuscular blockade at the
end of the surgical procedure, there were no differ-
ences in ephedrine and atropine use between groups.
4. Discussion
In humans, systemic lidocaine infusion was used for the
first time in 1951 by Gilbert et al. in different situations:
pancreatitis pain, analgesia for labour and metastatic
pain [12]. Three years later, De Clive-Lowe et al. used
intravenous lidocaine for the first time as adjuvant dur-
ing general anesthesia. They showed that lidocaine pro-
vides post-operative analgesia with low incidence of
post-operative nausea and vomiting [13]. Other studies
showed that the use of lignocaine with thiopentone
nitrous oxide-oxygen provide post-operative analgesia,
low incidence of nausea and vomiting, and short recov-
ery timewithout changes in pulse rate or blood pressure
[14,15]. In our study, we assessed the intraoperative
analgesic effects of a constant IV infusion of lidocaine
during lumbotomy in adult patients under general
anesthesia. We demonstrated, in this type of urologic
surgery, that IV infusion of lidocaine during general
anesthesia decreases isoflurane requirement, reduces
intraoperative remifentanil doses, and shortens time to
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Figure 1. Intra operative BIS.
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lidocaine decreases MAC of volatile anesthetic agents in
several species [3,16]. Lidocaine infusion seems to
decrease isoflurane MAC in anesthetized cats in a
dose-dependent manner [17]. In dogs, a bolus of
2 mg/kg followed by 100 µg/kg/min of lidocaine
allowed the investigators to reduce isoflurane MAC by
27.3% [18]. Although the analgesic effects of systemic
lidocaine have been demonstrated for chronic pain
especially the neuropathic type, the results for acute
pain have been contradictory [19]. Recent meta-analysis
[9] has found a significant difference in pain control at
rest, during cough, or during movement with the use of
intravenous lidocaine infusion in surgical patients under































Figure 3. Intra operative heart rate at all time point.
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Figure 4. Et-Isoflurane concentrations at all time point.
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Figure 5. MAC of Isoflurane at all time point.
* p < 10–3
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associated with a shorter hospital stay, decreased inci-
dence of nausea or vomiting, and faster return of bowel
function, with no impact on in-hospital mortality. These
differences were noticeable mainly in abdominal sur-
gery [9,20]. The effect of systemic lidocaine infusion in
urological surgery is poorly documented in the litera-
ture. Gourdine et al. [21] confirmed the benefit of a
continuous infusion of a small dose of lidocaine during
radical retropubic prostatectomy. First bowel move-
ment and flatus occurred faster in the lidocaine group
than the control group (17% vs 33%). Lidocaine-treated
patients had a two-thirds reduction in total pain score
compared with the control group. But in this work, the
authors did not study the effect of lidocaine on the
consumption of volatile anesthetic agents and opioids.
Lauwick et al. [22] assessed the effect of systemic lido-
caine infusion on post-operative functional walking
capacity as a measure of postsurgical recovery after
laparoscopic prostatectomy. Forty patients were
enrolled to receive either lidocaine infusion (bolus of
1.5 mg/kg followed by a continuous infusion 2 mg/kg/
h during surgery and 1 mg/kg/h in the PACU for 24h) or
same volume of normal saline (0.9% NaCl). In the lido-
caine group, patients were able to walk a longer dis-
tance over a short period of time (56 vs 43.5 m). The
authors attribute these results to the anti-inflammatory
action of lidocaine and its opioids-sparing effect in the
post-operative period. In this same study, the intrao-
perative consumption of desflurane dropped by 12%
(5.6 vs 6.3) in the lidocaine group while the BIS value
was similar in the two groups. However, the intraopera-
tive fentanyl use was not reduced in the lidocaine group
(250 µg vs 254 µg). Only one study had evaluated the
effect of IV lidocaine infusion during laparoscopic renal
surgery [23], and the authors did not find any significant
influence of lidocaine on the length of hospital stay,
post-operative pain, return of bowel function, or stress
responses. Also, fentanyl dosage did not differ signifi-
cantly between the two groups (lidocaine group: 810 µg
vs control group: 680 µg, p = 0.47). Similarly, there was
no volatile agent-sparing effect as assessed by isoflur-
ane MAC (lidocaine group: 0.86% vs control group:
0.93%). BIS monitoring was not performed in this
study unlike our trial. In this study, the investigators
used transperitoneal approach for the laparoscopic
renal surgery, with mobilization of the colon to access
the retroperitoneal space. In our study, the patients are
installed in the lumbotomy position and the retroper-
itoneal approach was used exclusively. To reach the
kidney, surgeons must swerve the latissimus dorsi, the
large external oblique, the large internal oblique and the
transverse abdominal muscles [24]. So we assume that
pain and inflammatory reactions are more pronounced
in the surgical compared to the laparoscopic approach,
although we have not measured inflammatory markers
during surgery. This idea was suggested by Wuethrich
et al. In fact, there were no significant changes in
Procalcitonin and C-Reactive Protein values observed
in their patients. It may reflect the lack of systemic
inflammatory response following thisminimally invasive
surgery [23]. In an observational study Tauzin-Fin et al.
showed that intravenous lidocaine improves post-
operative analgesia, reduces post-operative opioids
requirement, accelerates post operative recovery of
bowel function and facilitates acute rehabilitation in
patients undergoing laparoscopic nephrectomy.
Target-controlled infusion of sufentanil (Gepts pharma-
cokinetic model) was used during anesthesia with sevo-
flurane to maintain the BIS value between 40 and 50.
Intraoperative sufentanil consumption was similar for
both groups (139 µg vs 121 µg), and no difference in
time to tracheal extubation was noted [25]. Butterworth
et al. suggested inhibition of brain cell excitability as a
mechanism for analgesia from infused lidocaine by
increasing the current threshold of rat hippocampal
pyramidal cells. The lidocaine concentration used was
below those needed to block peripheral nerve conduc-
tion. This may underlie the analgesia and supplementa-
tion of general anesthesia produced by systemic
lidocaine infusion [26]. IV lidocaine also depresses
spike activity, amplitude and conduction time in both
myelinated A and unmyelinated C fibres [5,27].
Lidocaine anti-inflammatory activity may be another
potential mechanism in improving perioperative pain
by reducing cytokines release and neutrophil activation
[8]. It reduces spinal cord neurons activity and decreases
postsynaptic depolarization mediated by N-methyl-D-
aspartate (NMDA) [5]. Lidocaine infused intravenously
has analgesic, anti-hyperalgesic, anti-inflammatory
properties, and it also reduces intra- and post-operative
analgesic requirements [5]. The effect of systemic lido-
caine infusion on the MAC of volatile anesthetics is
partially elucidated. The anesthetic agents suppress
CNS Na+ channels in a voltage-dependent manner
[28]. Likewise, lidocaine action on both peripheral and
central nervous systems involves blockade of Na+ chan-
nels [5]. So both inhalant anesthetics and lidocaine act
on voltage-gated Na+ channels in the central nervous
system [28] and thus their effects during general
anesthesia could be additive. Lidocaine ensures pain
relief on the spinal level [29], which presupposes a
reduction in MAC and decreases the volatile agents
demand. Finally, lidocaine is capable of blocking brain
cell excitability, and this could explain both its analgesic
and MAC-reducing properties [17,26]. These observa-
tions have been made in several animal studies
[4,17,18]. Our results are consistent with previous
reports in which IV lidocainewas found to reduce intrao-
perative opioid use. We found an opioid sparing effect
in the intraoperative period in the lidocaine group
allowing us to decrease remifentanil dosage by 27%. A
literature search yielded only a few studies in which
remifentanil was used as the opioid in conjunction
with intraoperative systemic lidocaine infusion. Uzun
LIBYAN JOURNAL OF MEDICINE 5
et al. report that perioperative IV lidocaine infusion had
no significant effect on remifentanil use during hypo-
tensive anesthesia for transsphenoidal endoscopic
hypophyseal adenoma excision [30]. Kaba et al. found
that the total dose of sufentanil given to patients in the
lidocaine group during laparoscopic colectomy was sig-
nificantly lower than in the control group (13.0 ± 3.7 µg
versus 16.3 ± 3.6 µg) [7]. A similar result was obtained in
ambulatory surgery where lidocaine use yielded a 30%
reduction in intraoperative opioid use [31]. In another
study, in patients undergoing laparoscopic cholecys-
tectomy, the total fentanyl consumption was found to
be significantly lower in the lidocaine group
(242 ± 48.5 µg vs 323 ± 70.8 µg) [32]. It should be
pointed out the evidence for an opioid sparing effect
of systemic lidocaine is not consistently clear in the
published clinical literature regardless of whether lido-
caine is used with volatile or intravenous anesthesia
[11,22,23,25,30,33]. However, the evidence is strong in
support of the effect of systemic lidocaine in reducing
the total dose of volatile anesthetic required for general
anesthesia. Overall, these observations appear are con-
sistent with those made in animal studies. Sevoflurane
requirement was significantly reduced during abdom-
inal surgery as monitored by BIS at all intraoperative
time points [11]. The same result was found in different
types of surgeries using sevoflurane [7,11,32,34] and
desflurane [6,22,27]. Similarly, systemic lidocaine
allowed Altermatt et al. to reduce propofol requirement
during the maintenance of total intravenous anesthesia
for laparoscopic cholecystectomy as measured by BIS.
However, Wuethrich et al. does not find a decrease in
isoflurane MAC during laparoscopic renal surgery when
using systemic lidocaine administration.
The metabolic and the endocrine responses as mea-
sured by serum cortisol, C-reactive protein (CRP and
procalcitonin did not differ in the lidocaine and control
group [23]. These findings can be explained by the lack
of a major inflammatory reaction following laparo-
scopic renal surgery unlike colonic surgery. In the pre-
sent study we demonstrated that systemic lidocaine
administration during renal surgery in the lumbotomy
position has a synergistic effect on narcosis by sparing
isoflurane requirement in adults, as monitored by BIS.
We also showed improved analgesia resulting in
reduced remifentanil dosage. Another important result
of our study is that lidocaine significantly shortens the
time to extubation. With respect to hemodynamics, the
MAP values were comparable in the two groups, while
the mean heart rate was lower in the lidocaine group.
This significant negative chronotropic effect is likely the
result of the direct depression of the sinus node and
sympathetic tone blockade [35]. This observation is
particularly important for patients with severe coronary
artery disease. The protocol of administering a loading
dose followed by a continuous IV infusion of lidocaine
during general anesthesia has been used in several
previous investigations [7,10,11,31,33]. The doses used
are calculated to achieve a plasma lidocaine concentra-
tion well below the toxic levels (> 5 µg/ml) [7,21].
Plasma levels of lidocaine were not determined in our
patients because this service is not available in our
institution.
Lidocaine has neurological and cardiac toxicity.
Perioral paresthesia, metallic taste, dizziness, slurred
speech, diplopia, tinnitus, confusion, agitation and mus-
cular spasms occur with high lidocaine serum level (>
5 µg/ml). Seizures indicate severe intoxication, which is
due to inhibition of inhibitory neurons by gamma-ami-
nobutyric acid receptors in the cerebral amygdala.
Bradycardia with an increase in PR interval and widen-
ing QRS complex is seen in cardiovascular toxicity [5].
There are some limitations in our study. We
focused on lidocaine effect only during intraoperative
period. We have not evaluated its effects after the
surgery especially on pain relief, nausea and vomiting
and hospital stay. Another limitation is the heteroge-
neity of the patients’ ages, which mean that MAC and
requirement in isoflurane are not uniform especially in
elderly patients. Also, the pharmacoeconomic impact
of lidocaine was not addressed in our study.
Nevertheless, reducing isoflurane needs by 31% and
remifentanil consumption by 27% seems to be a key
factor in minimizing anesthesia costs for renal surgery.
5. Conclusion
Intravenous lidocaine infusion during general
anesthesia for renal surgery decreases BIS-guided iso-
flurane needs and remifentanil consumption. The low
cost of this drug and its attractive profile regarding
side effects could provide effective strategies to limit
volatile agent and intra-operative opioids consump-
tion, especially in low- and middle-income countries.
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